AT149124B - Process for the manufacture of an agent for inhibiting and abolishing pathological secretion of the nasal mucous membranes. - Google Patents

Process for the manufacture of an agent for inhibiting and abolishing pathological secretion of the nasal mucous membranes.

Info

Publication number
AT149124B
AT149124B AT149124DA AT149124B AT 149124 B AT149124 B AT 149124B AT 149124D A AT149124D A AT 149124DA AT 149124 B AT149124 B AT 149124B
Authority
AT
Austria
Prior art keywords
agent
abolishing
inhibiting
mucous membranes
manufacture
Prior art date
Application number
Other languages
German (de)
Original Assignee
Oesterreichische Serum Ges M B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oesterreichische Serum Ges M B filed Critical Oesterreichische Serum Ges M B
Application granted granted Critical
Publication of AT149124B publication Critical patent/AT149124B/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Description

  

   <Desc/Clms Page number 1> 
 



  Verfahren zur Herstellung eines Mittels zur Hemmung und Aufhebung der pathologischen Sekretion der Nasenschleimhäute.   fie Jjjimaung oezient sien aut em venanren zur Herstellung eines Mittels, dureh weiches die   pathologisch Sekretion der Nasenschleimhaut gehemmt und aufgehoben wird. Versuche, welche angestellt wurden, haben ergeben, dass Schlangengift, wie solches von Crotalos, Kobra, Vipern, in einer geeigneten Salbengrundlage die Eigenschaft besitzt, verschiedene Nasenleiden zu heilen. Gute Erfolge wurden beispielsweise erzielt bei Rhinitis vasomotoria, Heuschnupfen, Rhinitis ehronica und akutem Schnupfen. Auch bei schwerer Ozaena hat sich das Mittel bewährt. 



   Es genügt, geringe Mengen des Schlangengiftes der Salbengrundlage einzuverleiben. Dasselbe kann vorteilhaft mit Stoffen kombiniert werden, welche die Resorption durch die Haut fördern, wie z. B. Saponin, Triäthanolamin. Es können auch Zusätze von Mitteln erfolgen, welche resorbiert werden und dadurch die Giftwirkung fördern, wie z. B. Salizylsäure und ihre Salze. Ferner können auch solche Zusätze erfolgen, welche gleichzeitig eine Hyperämisierung hervorrufen. Je nach Umständen kann hiedurch der therapeutische Effekt entsprechend eingeregelt werden. 



   Beispielsweise kann die Salbe in der Weise hergestellt werden, dass in 200   CM3   Wasser 1 g des in üblicher Weise beschaffen Schlangengiftes versetzt und diese Lösung mit weiteren 200 g Euzerin, 
 EMI1.1 
 zweimal täglich an beiden Armen des Patienten abwechselnd in die Haut eingerieben werden. Je nach der Schwere des Krankheitszustandes wird der Heilungseffekt in kürzester oder nach längerer Zeit in Erscheinung treten. 

**WARNUNG** Ende DESC Feld kannt Anfang CLMS uberlappen**.



   <Desc / Clms Page number 1>
 



  Process for the manufacture of an agent for inhibiting and abolishing pathological secretion of the nasal mucous membranes. The Jjjimaung oezient sien aut em venanren for the production of an agent by which the pathological secretion of the nasal mucous membrane is inhibited and canceled. Experiments which have been carried out have shown that snake venom, such as that of Crotalos, cobra, vipers, in a suitable ointment base has the property of curing various nasal ailments. Good results have been achieved, for example, with rhinitis vasomotoria, hay fever, rhinitis ehronica and acute rhinitis. The remedy has also proven itself in severe ozaena.



   It is sufficient to incorporate small amounts of the snake venom into the ointment base. The same can advantageously be combined with substances that promote absorption through the skin, such as. B. saponin, triethanolamine. There can also be additions of agents which are absorbed and thereby promote the poisonous effect, such as. B. Salicylic acid and its salts. Furthermore, such additives can also be made which simultaneously cause hyperaemia. Depending on the circumstances, the therapeutic effect can be adjusted accordingly.



   For example, the ointment can be prepared in such a way that 1 g of the snake venom obtained in the usual way is added to 200 cm3 of water and this solution with another 200 g of Euzerin,
 EMI1.1
 alternately rubbed into the skin on both arms of the patient twice a day. Depending on the severity of the disease, the healing effect will appear in a very short time or after a longer period of time.

** WARNING ** End of DESC field may overlap beginning of CLMS **.

 

Claims (1)

PATENT-ANSPRUCH : Verfahren zur Herstellung eines Mittels zur Hemmung und Aufhebung der pathologischen Sekretion der Nasenschleimhäute, dadurch gekennzeichnet, dass Schlangengift mit Stoffen kombiniert wird, welche leicht in die Oberhaut eindringen. **WARNUNG** Ende CLMS Feld Kannt Anfang DESC uberlappen**. PATENT CLAIM: Process for producing an agent for inhibiting and abolishing the pathological secretion of the nasal mucous membranes, characterized in that snake venom is combined with substances which easily penetrate the epidermis. ** WARNING ** End of CLMS field may overlap beginning of DESC **.
AT149124D 1936-06-09 1936-06-09 Process for the manufacture of an agent for inhibiting and abolishing pathological secretion of the nasal mucous membranes. AT149124B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT149124T 1936-06-09

Publications (1)

Publication Number Publication Date
AT149124B true AT149124B (en) 1937-04-10

Family

ID=3645473

Family Applications (1)

Application Number Title Priority Date Filing Date
AT149124D AT149124B (en) 1936-06-09 1936-06-09 Process for the manufacture of an agent for inhibiting and abolishing pathological secretion of the nasal mucous membranes.

Country Status (1)

Country Link
AT (1) AT149124B (en)

Similar Documents

Publication Publication Date Title
AT149124B (en) Process for the manufacture of an agent for inhibiting and abolishing pathological secretion of the nasal mucous membranes.
AT142023B (en) Process for the manufacture of an agent for protecting the epidermis against infection and for healing skin diseases.
AT200262B (en) Process for the production of durable water-containing solutions of pure cardiac glycosides
WO1991004752A1 (en) Eye-drops
DE463805C (en) Process for the preparation of durable, sterilizable solutions which contain phosphorus in organic bonds and bound gold
AT107599B (en) Process for the preparation of durable, sterilizable solutions, which contain phosphorus in organic bonds as well as bound gold.
AT157575B (en) Process for the production of undecomposed, sterilizable drug solutions from the double compound theophylline-piperazine.
US2025399A (en) Topical anzesthetic
DE431847C (en) Process for the production of intravenous injectable preparations against bilharzia
AT129939B (en) Process for the production of a wound ointment.
DE752680C (en) Anion exchange
DE695034C (en) Process for the preparation of durable solutions of p-aminobenzenesulfonamide
AT112734B (en) Process for the preparation of monocamphorates of the Solanaceae alkaloids.
DE576445C (en) Process for the production of primula acid (primula saponin) from primula species
DE427668C (en) Process for the preparation of quinine solutions suitable for subcutaneous injections
DE544678C (en) Disinfectants
AT133895B (en) Process for the preparation of acylaminobenzenestibinic acids.
DE819127C (en) Process for the preparation of a therapeutic bath against skin eczema
AT133143B (en) Process for the preparation of readily soluble sodium salts of 4-oxy-3-acylaminobenzolaric acids (1) or their substitution products.
AT142163B (en) Process for the manufacture of preparations for sunlight treatment.
DE1518102C3 (en) Process for the preparation of a pure water-soluble condensation product suitable for therapeutic purposes from m-cresol sulfonic acid and formaldehyde
AT132570B (en) Process for the production of primula saponin from primula species.
AT166471B (en)
AT68796B (en) Process for the production of tanning preparations which are easily soluble in cold water.
AT203000B (en) Process for the preparation of new salts of 4,6-dioxyisophthalic acid and 5-halogen (especially 5-iodine) - 4,6-dioxyisophthalic acid